Recognition highlights Clairity’s mission to shift breast cancer care from late-stage treatment to proactive prevention

Clairity, Inc., a company pioneering AI-powered risk prediction in human health, today announced that Founder Dr. Connie Lehman has been named to the Forbes “50 Over 50: Innovation” list. This annual ranking celebrates women who are breaking boundaries and advancing bold solutions to global challenges. Dr. Lehman will be honored at the Forbes & Mika Brzezinski 50 Over 50 Celebration on November 4, 2025, in New York City.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015827825/en/

Dr. Connie Lehman, Founder of Clairity

Why This Matters

Breast cancer remains the most common cancer among women worldwide, and most women diagnosed have no family history of the disease. Early identification of women at higher risk is critical because it allows healthcare providers to recommend more personalized screening and prevention strategies. By applying AI directly to a woman’s routine mammogram, CLAIRITY BREAST can provide risk information that is more precise and equitable than traditional models, helping ensure that every woman gets the right care at the right time.

Dr. Lehman founded Clairity in 2020 to transform breast cancer care by shifting the focus from reactive diagnosis to proactive prevention. Earlier this year, Clairity achieved a major milestone when the U.S. Food and Drug Administration (FDA) granted De Novo authorization to CLAIRITY BREAST, the first FDA-authorized platform to predict five-year breast cancer risk from a routine screening mammogram.

“This honor reflects the collective effort of scientists, clinicians, and innovators applying AI to serve humanity — and, in this case, to confront the global challenge of breast cancer,” said Dr. Lehman. “Traditional risk models have been limited by the data and populations on which they were built. With CLAIRITY BREAST, we’re ensuring every woman, regardless of race or ethnicity, can receive risk information that is both accurate and equitable. Bringing this technology into healthcare systems this year is a critical step toward truly personalized and preventive care.”

Internationally recognized as a leader in breast imaging and cancer risk assessment, Dr. Lehman has authored more than 300 peer-reviewed publications spanning computer-aided diagnosis, deep learning, risk modeling, and advancements in breast cancer screening and diagnosis. She is Professor of Radiology at Harvard Medical School and a Breast Imaging Specialist at Mass General Brigham.

About CLAIRITY BREAST

CLAIRITY BREAST, authorized by the FDA under the name Allix5, is a mammography-based AI risk prediction platform that analyzes imaging data at the pixel level to identify individuals at elevated risk of future breast cancer. The AI model behind CLAIRITY BREAST was developed using 421,499 mammograms from 27 facilities across Europe, South America, and the U.S., and validated on more than 120,000 mammograms from ten geographically distinct U.S. screening centers, representing a diverse patient population. Validation was anchored in five-year outcome data. To learn more about indications for use, visit: https://clairity.com/clairity-breast/

About Clairity

Founded in 2020 and headquartered in Boston, Massachusetts, Clairity, Inc. is transforming healthcare risk assessment through the power of artificial intelligence and deep learning. Backed by Santé Ventures, ACE Global Equity, and Breast Cancer Research Foundation, Clairity's platform can uncover subtle patterns in routine images that are invisible to the human eye, enhancing risk prediction to empower clinicians and their patients with actionable, personalized insights. Clairity’s mission is to shift the standard of care from late-stage treatment to proactive prevention across human health. To learn more, visit us at www.clairity.com | LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20251015827825/en/

Dr. Lehman will be honored at the Forbes & Mika Brzezinski 50 Over 50 Celebration on November 4, 2025, in New York City.